본문으로 건너뛰기
← 뒤로

A Rare Primary Adrenal Malignancy Manifesting as a Hemorrhagic Mass: Case Report and Literature Review.

Case reports in endocrinology 2026 Vol.2026() p. 1260707

Ghaithi SA, Alali I, Reesi AA, Almadhani A

📝 환자 설명용 한 줄

Primary adrenal extranodal natural killer/T-cell lymphoma (ENKTL) is an exceptionally rare, aggressive malignancy with fewer than 10 cases worldwide.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Ghaithi SA, Alali I, et al. (2026). A Rare Primary Adrenal Malignancy Manifesting as a Hemorrhagic Mass: Case Report and Literature Review.. Case reports in endocrinology, 2026, 1260707. https://doi.org/10.1155/crie/1260707
MLA Ghaithi SA, et al.. "A Rare Primary Adrenal Malignancy Manifesting as a Hemorrhagic Mass: Case Report and Literature Review.." Case reports in endocrinology, vol. 2026, 2026, pp. 1260707.
PMID 41959648

Abstract

Primary adrenal extranodal natural killer/T-cell lymphoma (ENKTL) is an exceptionally rare, aggressive malignancy with fewer than 10 cases worldwide. We describe a 55-year-old man with diabetes mellitus and benign prostatic hyperplasia who presented with progressive left-sided abdominal pain and a 17-kg unintentional weight loss over 4 months. Imaging showed a 4.9-cm left adrenal mass with hemorrhagic features, initially presumed to be spontaneous adrenal hemorrhage. Endocrine evaluation excluded functional adrenal tumors, and surgical management required conversion from laparoscopic adrenalectomy to open resection due to superior mesenteric vein (SMV) involvement. Histopathological and immunophenotypic confirmed non-nasal ENKTL (CD3+, CD56+, granzyme B+, perforin+, and Epstein-Barr virus-encoded RNA [EBER]+). Postoperative F-FDG PET/computed tomography (CT) demonstrated residual disease; steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy achieved a marked complete metabolic response after six cycles-one of the most significant documented responses in primary adrenal NK/T-cell lymphoma. This case highlights diagnostic challenges of primary adrenal lymphoma (PAL), the need for histopathological confirmation in atypical masses, and suspicion for hematological malignancies with systemic symptoms and adrenal lesions.